Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02161458 · ClinicalTrials.gov registry record · Phase 4
Escitalopram Effects on CSF Amyloid Beta
A Phase 4 study of Amyloid Beta-protein, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 98
- Enrollment target
- 2
- Study locations
NCT02161458 is a Phase 4 study of Amyloid Beta-protein that has completed, run by University of Pennsylvania. The registered enrollment target is 98 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT02161458, a Phase 4 study of Amyloid Beta-protein, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 98 participants
- Enrollment target
- 2
- Study locations
Study Summary
Alzheimers disease (AD) is a devastating illness, estimated to affect 5 million patients in the United States alone and projected to increase dramatically over the next decades as the population ages unless preventive measures can be developed. The investigators have preliminary evidence that selective serotonin reuptake inhibitor (SSRI) antidepressants lower the amount of amyloid plaques in the human brain. The interventions now propose to study the effects of an SSRI (escitalopram) on levels of amyloid beta peptide (the major constituent of the plaques) in the cerebrospinal fluid (CSF) of cognitively normal older adults.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Escitalopram 20mg for 2 weeks
- DRUG Escitalopram 20mg for 8 weeks
- DRUG Escitalopram 30mg for 8 weeks
Study Locations (2)
Missouri
- Washington University - St Louis
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2014-06 |
| Est. Completion | 2019-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02161458
The ClinicalTrials.gov registry entry for NCT02161458 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyloid Beta-protein appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT02161458 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Missouri, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02161458 about?
NCT02161458 is a clinical study titled "Escitalopram Effects on CSF Amyloid Beta". Alzheimers disease (AD) is a devastating illness, estimated to affect 5 million patients in the United States alone and projected to increase dramatically over the next decades as the population ages unless preventive measures can be developed. The investigators have preliminary evidence that select...
What is the current status of trial NCT02161458?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 98 participants. The study started on 2014-06. Estimated completion is 2019-01.
What conditions does trial NCT02161458 study?
This clinical trial studies the following conditions: Amyloid Beta-protein.
What interventions are being tested in trial NCT02161458?
The interventions under investigation include: Placebo (DRUG), Escitalopram 20mg for 2 weeks (DRUG), Escitalopram 20mg for 8 weeks (DRUG), Escitalopram 30mg for 8 weeks (DRUG).
Who is sponsoring clinical trial NCT02161458?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02161458 being conducted?
This trial has 2 study locations across Missouri, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyloid Beta-protein
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.